Florida medical tech company launches novel AI test for prostate cancer therapy

Dr. Dan Spratt, chair of the Department of Radiation Oncology at University Hospitals Cleveland Medical Center, talks about how ArteraAI's Prostate Test is helping him to identify optimal therapies for his patients. Prostate cancer is the second leading cause of cancer death in men in the U.S., with an expected 288,000 cases and 34,700 deaths expected in 2023, per the American Cancer Society. As artificial intelligence-based health technologies continue to advance, a growing number of medical tech firms are looking to use AI to improve patient outcomes. One of these is ArteraAI, a firm in Jacksonville, Florida, that develops medical AI tests that help personalize therapy for cancer patients. Among the company's solutions is the ArteraAI Prostate Test, described as the first of its kind for patients with localized prostate cancer.